Paris, France

Guillaume Begis

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Paris, FR (2013 - 2014)
  • Versailles, FR (2015)

Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Innovations by Inventor Guillaume Begis

Introduction

Guillaume Begis is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. With a total of 4 patents to his name, his work focuses on addressing critical health issues, including cardiovascular diseases and diabetes-related complications.

Latest Patents

Among his latest patents, Guillaume Begis has developed 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases. This invention relates to compounds that have therapeutic applications in managing heart-related conditions. Another significant patent involves 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives, which serve as kinase inhibitors. These compounds are particularly useful in treating diseases associated with diabetes and its complications, such as diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy.

Career Highlights

Guillaume Begis is currently employed at Sanofi, a leading global healthcare company. His work at Sanofi has allowed him to focus on innovative solutions that address pressing health challenges. His expertise in the field has positioned him as a valuable contributor to the company's research and development efforts.

Collaborations

Guillaume has collaborated with several professionals in his field, including Olivier Duclos and Gary McCort. These collaborations have enhanced the scope and impact of his research, leading to advancements in pharmaceutical innovations.

Conclusion

In summary, Guillaume Begis is a prominent inventor whose work in developing kinase inhibitors has the potential to significantly improve treatment options for cardiovascular diseases and diabetes-related complications. His contributions to the pharmaceutical industry are noteworthy and continue to influence advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…